Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. The Company expects to announce a transition from the dose escalation to dose expansion phase in the second half of 2024 EXS74539 (‘539) The Company’s differentiated MALT1 inhibitor, precision designed with selectivity over UGT1A1, is also advancing through IND-enabling studies. This collaboration highlights the s